Daily Stock Analysis, GCVRZ, Sanofi SA, priceseries

Sanofi SA. Daily Stock Analysis
Stock Information
Open
0.51
Close
0.51
High
0.51
Low
0.49
Previous Close
0.52
Daily Price Gain
-0.02
YTD High
0.52
YTD High Date
Feb 20, 2019
YTD Low
0.42
YTD Low Date
Jan 15, 2019
YTD Price Change
0.04
YTD Gain
9.78%
52 Week High
0.60
52 Week High Date
Sep 17, 2018
52 Week Low
0.20
52 Week Low Date
Oct 9, 2018
52 Week Price Change
0.11
52 Week Gain
27.14%
Company Information
Stock Symbol
GCVRZ
Exchange
NYSE
Company URL
http://www.sanofi.com
Company Phone
33153774400
CEO
Olivier Brandicourt
Headquarters
-
Business Address
54 RUE LA BOETIE, PARIS, FRANCE 75008
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001121404
About

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following segments: Pharmaceuticals, Human Vaccines, and Animal Health. The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products. This segment also includes equity affiliates and joint ventures with pharmaceutical business activities. The Human Vaccines segment includes research, development, production and marketing of vaccines. The Animal Health segment comprises the research, development, production and marketing activities for Merial, which offers a range of medicines and vaccines for animal species. The company was founded on April 28, 1994 and is headquartered in Paris, France.

Description

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.